Pierre Feugier

机构：Inserm, Centre Hospitalier Régional et Universitaire de Nancy, Centre d’Investigation Clinique Innovation Technologique de Nancy, Nutrition-Génétique et Exposition aux Risques Environnementaux, Université de Lorraine

发表论文 190 篇 · 总被引 11463 次 · h-index 47

代表论文

• Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial (2023 · Nature Medicine · 被引 101)
• Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial (2022 · Journal of Clinical Oncology · 被引 80)
• High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network (2022 · Journal of Clinical Oncology · 被引 60)
• Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study (2025 · Nature Cancer · 被引 40)
• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 28)
• Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial (2023 · Journal of Clinical Oncology · 被引 19)